Orphazyme A/S
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. The company was founded in 2009 and is based in Herlev, Denmark.
Market Cap & Net Worth: Orphazyme A/S (OZYMF)
Orphazyme A/S (PINK:OZYMF) has a market capitalization of $3.72 Million ($3.72 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #35050 globally and #11432 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orphazyme A/S's stock price $90.00 by its total outstanding shares 41349 (41.35K).
Orphazyme A/S Market Cap History: 2019 to 2025
Orphazyme A/S's market capitalization history from 2019 to 2025. Data shows change from $458.15 Million to $3.72 Million (-54.93% CAGR).
Orphazyme A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orphazyme A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.29x
Orphazyme A/S's market cap is 3.29 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $119.09 Million | $36.19 Million | -$626.54 Million | 3.29x | N/A |
Competitor Companies of OZYMF by Market Capitalization
Companies near Orphazyme A/S in the global market cap rankings as of March 18, 2026.
Key companies related to Orphazyme A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Orphazyme A/S Historical Marketcap From 2019 to 2025
Between 2019 and today, Orphazyme A/S's market cap moved from $458.15 Million to $ 3.72 Million, with a yearly change of -54.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.72 Million | 0.00% |
| 2024 | $3.72 Million | 0.00% |
| 2023 | $3.72 Million | 0.00% |
| 2022 | $3.72 Million | -96.88% |
| 2021 | $119.09 Million | -76.77% |
| 2020 | $512.73 Million | +11.91% |
| 2019 | $458.15 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Orphazyme A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.72 Million USD |
| MoneyControl | $3.72 Million USD |
| MarketWatch | $3.72 Million USD |
| marketcap.company | $3.72 Million USD |
| Reuters | $3.72 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.